TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06679530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful Music Listening (MML)
Description: Self-guided mindful music listening intervention comprised of 1-hour daily music listening during inpatient hospitalization.
Study: NCT05675332

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Task-based behavioral intervention
Description: Brief behavioral intervention is absent of stressors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Task-based behavioral intervention
Description: Brief behavioral intervention involves interacting with common everyday types of stress.
Study: NCT04535843

Intervention type: DEVICE
Intervention: pheripheral biomarkers or omics data
Description: To detect pheripheral biomarkers and omics data,including lymphocytes and cytokines, in this prospective MG cohort.
Study: NCT06284538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NOVA.EMOSTOP RE-EPITHELIZING
Description: RE-EPITHELIZING GEL BASED ON HYALURONIC ACID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVA.EMOSTOP RE-EPITHELIZING
Description: RE-EPITHELIZING GEL BASED ON HYALURONIC ACID
Study: NCT05999006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELIOS Procedure
Description: Treatment with the ELIOS System
Study: NCT06381661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50mg (in children: 1-2 mg/kg) IV Q6 for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and fludrocortisone
Description: Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanThrombomodulin( rhTM)
Description: Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat
Description: 0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: 12 ml/kg/day as long as INR remains \>1.4

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT05293847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercises and postural skills
Description: 12 week based postural exercises and skills were applied to participants. The exercises were done 3 times a week. The exercises about cervical and thoracal region strengthening and stretching of muscles and structures.
Study: NCT05612932

Intervention type: OTHER
Group type: OTHER
Intervention: immediate orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer immediately after debonding

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed orthodontic retainer delivery
Description: post orthodontic treatment patients will be given orthodontic retainer after 7 days of debonding
Study: NCT04709627

Intervention type: DEVICE
Intervention: enFlow IV Fluid and Blood Warming System
Description: The enFlow IV fluid/blood warming system's intended use is for warming blood, blood products and intravenous solutions prior to administration.
Study: NCT05630963

Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).

Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).

Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).

Intervention type: DRUG
Intervention: PET radiotracer
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.

Intervention type: DRUG
Intervention: PET radiotracer
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.

Intervention type: DRUG
Intervention: PET radiotracer
Description: A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels.
Study: NCT05856695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Paclitaxel + Durvalumab
Description: Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
Study: NCT06388902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR115 for injection
Description: BR115 for injection will be administered by subcutaneous injection, two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data.
Study: NCT05358132

Intervention type: DEVICE
Intervention: Pneumowave Device placement and data capture
Description: Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,

Intervention type: DEVICE
Intervention: Pneumowave Device placement and data capture
Description: Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,
Study: NCT05925205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle energy technique combined with the physical therapy program.
Description: A manual therapy technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strain counterstrain technique combined with the physical therapy program
Description: A manual therapy technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The physical therapy program
Description: Electrotherapy and exercise.
Study: NCT05876403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
Study: NCT05158855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis spore extract
Description: Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
Study: NCT05463653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: A digital pad developed to help, support and monitor the adherence of patients to rehabilitation excercices post surgery
Study: NCT05506462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride
Study: NCT05896436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Focused Therapy
Description: 12 sessions of Emotion Focused Therapy (EFT). The focus in EFT is to promote the individual's experiencing and facilitate participants' self-disclosure and openness to their own experience, rather than the therapist's agenda or techniques. Key processes within EFT include helping people overcome their avoidance of emotion, maintaining a collaborative focus on emotions, and exploring emotions in therapy.
Study: NCT04772326

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire
Study: NCT04756336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-109 gel, 3% w/w
Description: The drug is applied to affected lesions according to treatment regimen
Study: NCT04588103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Lower limb warm water immersion (42 degrees C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: Lower limb warm water immersion (42 degrees C)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Moderate-intensity cycling exercise (\~40-59% VO2 reserve)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Moderate-intensity cycling exercise (\~40-59% VO2 reserve)
Study: NCT05949307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser acupuncture
Description: Sham-laser acupuncture
Study: NCT05214001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 Mg Oral Tablet
Description: Treatment for an acute, moderate to severe migraine attack

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ubrogepant 50Mg Tab
Description: Treatment for an acute, moderate to severe migraine attack
Study: NCT05412173

Intervention type: DRUG
Group type: OTHER
Intervention: Molnupiravir
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Molnupiravir
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT06213844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3002
Description: Single dose of IBI3002 (Dosage 1, Dosage 2, Dosage 3, Dosage 4, Dosage 5, Dosage 6), administered subcutaneously on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo, administered subcutaneously on Day 1
Study: NCT05448430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: a new paradigm of high frequency repetitive transcranial magnetic stimulation
Study: NCT04723810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: The investigational drug is indocyanine green, single dose between 1-5 mg/kg diluted into sterile water for intravenous (IV) injection up to 5 days prior to resection surgery. The actual dose and timing from dose to imaging will be determined based on tumor type.
Study: NCT05341622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated Box
Description: Patients will receive mailed FIT kits in a box with differentiated packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated Box
Description: Patients will receive mailed FIT kits in a box with differentiated packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated Box
Description: Patients will receive mailed FIT kits in a box with differentiated packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Differentiated Box
Description: Patients will receive mailed FIT kits in a box with differentiated packaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Mail
Description: Patients will receive mailed FIT in a standard mailing envelope

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Mail
Description: Patients will receive mailed FIT in a standard mailing envelope

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Mail
Description: Patients will receive mailed FIT in a standard mailing envelope

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Mail
Description: Patients will receive mailed FIT in a standard mailing envelope

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text
Description: Patients will receive a series of up to 3 texts explaining the importance of colon cancer screening and prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Text
Description: Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Text
Description: Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.
Study: NCT06277843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Jacket
Description: In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention (Thermal Jacket) as a supplement of Kangaroo Mother Care (KMC).
Study: NCT05341622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Text
Description: Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Text
Description: Patients will not receive text messaging explaining the importance of colon cancer screening or prompts to complete the mailed FIT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Patients will receive a mailed letter reminder to complete their FIT kit if not resulted by 1 month from initial outreach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Reminder
Description: Patients will not receive any mailed letter reminder to complete their FIT kit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Reminder
Description: Patients will not receive any mailed letter reminder to complete their FIT kit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Reminder
Description: Patients will not receive any mailed letter reminder to complete their FIT kit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Reminder
Description: Patients will not receive any mailed letter reminder to complete their FIT kit.
Study: NCT05130554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XEN45 gel stent implantation
Description: The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance.This treatment method has excellent safety and effectiveness in reducing the intraocular pressure of patients with open-angle glaucoma. At the same time, the operation is simple and safe.
Study: NCT06192173

Intervention type: PROCEDURE
Intervention: Percutaneous PFO closure
Description: Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.
Study: NCT06293976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in the ventilator respiratory rate and tidal volume
Description: With the ventilator on volume control and Vt at 6 ml/kg of predicted body weight (PBW) (standard clinical practice), an end-expiratory occlusion of 30 seconds on the ventilator will be performed to search for intrinsic respiratory rate (RR). The set RR will be modified from 6 breaths per minute (bpm) below up to 6 bpm above the clinical RR in steps of 2 bpm every 1 minute (random order). The changes in RR described above will be repeated with Vt set at 5, 7 and 8 ml/kg PBW (random order). The steps described above will be aborted at any point if SpO2 drops below 85% for at least two minutes, mean arterial pressure drops below 60 mmHg, or plateau pressure \>35 cmH2O.~If an intrinsic respiratory rate ≥8 bpm is present and P/F ratio is ≥150, it will be propose to the clinician to place the patient in pressure support at a level preferred by clinicians for 5 minutes. If the patient tolerates well, it will be propose to the clinician to maintain the patient in pressure support ventilation,
Study: NCT05067309

Intervention type: DRUG
Intervention: Letrozole 2.5mg
Description: Missed abortion received letrozole then misoprostol
Study: NCT05227092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D OPTIMIZED WMN MPRAGE
Description: * At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set.
Study: NCT05271500

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture
Description: gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: laser acupuncture
Description: gallium-aluminum arsenide diode laser with a continuous wave and a wavelength of 850nm will be used for laser acupuncture. it will be applied for three times per week for 12 weeks